GC BIOPHARMA CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114,300 KRW | -0.70% |
|
+2.05% | -8.92% |
Chart calendar GC Biopharma Corp.
5da6a45764d.ahSh9r7iYaYJmtiwa_QKqJWlSnlHf1e0ilWyazt0hdQ.B2TJuMmNCshZ163pWZhk46bjDiwGD2XY5GzYJmlEwIYQXNSG1psXl1qutw~52ba289af1e4cb07740f88af3cbdb1e2
Upcoming events on GC Biopharma Corp.
Past events on GC Biopharma Corp.
| 08/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 3595 |
| 08/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 1324 |
| 19/03/2024 | Q4 2023 Earnings Release |
| 31/01/2024 05:00 | GC Biopharma Investor Day |
| 26/12/2023 | Ex-dividend day for final dividend |
| 31/10/2023 | Q3 2023 Earnings Release |
| 01/08/2023 | Q2 2023 Earnings Release (Projected) |
| 14/05/2023 | Q1 2023 Earnings Release |
| 20/03/2023 | Q4 2022 Earnings Release |
| 27/12/2022 | Ex-dividend day for final dividend |
| 13/11/2022 | Q3 2022 Earnings Release |
| 28/08/2022 11:15 | Pharmacoepidemiology & Therapeutic Risk Management International Conference - Abstract #1016 |
| 15/08/2022 | Interim 2022 Earnings Release |
| 15/05/2022 | Q1 2022 Earnings Release |
| 14/02/2022 10:30 | FY 2021 Earnings Release |
| 28/12/2021 | Ex-dividend day for final dividend |
| 01/11/2021 07:41 | Q3 2021 Earnings Release |
| 02/08/2021 06:20 | Interim 2021 Earnings Release |
| 29/04/2021 02:27 | Q1 2021 Earnings Release |
| 16/03/2021 | FY 2020 Earnings Release |
Past dividends on GC Biopharma Corp.
| 26/12/2023 | Annual 1500 KRW |
| 27/12/2022 | Annual 1750 KRW |
| 28/12/2021 | Annual 2000 KRW |
| 28/12/2020 | Annual 1500 KRW |
| 26/12/2019 | Annual 1000 KRW |
| 26/12/2018 | Annual 1000 KRW |
| 26/12/2017 | Annual 1250 KRW |
| 27/12/2016 | Annual 1250 KRW |
| 28/12/2015 | Annual 1750 KRW |
| 28/12/2014 | Annual 1250 KRW |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Billions KRW | Released Forecast Spread | 1 370 1 359 0.81% | 1 504 1 488 1.06% | 1 538 1 605 -4.19% | 1 711 1 702 0.55% | 1 627 1 649 -1.33% | 1 744 |
|
EBITDA Billions KRW | Released Forecast Spread | 79,9 105 -23.99% | 99,0 128 -22.75% | 130 168 -23.09% | 146 168 -12.91% | 110 107 2.88% | 134 |
|
EBIT Billions KRW | Released Forecast Spread | 40,3 61,3 -34.36% | 50,3 81,9 -38.65% | 73,7 118 -37.41% | 81,3 104 -22.19% | 34,4 33,3 3.46% | 62,8 |
|
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | -6,14 37,6 -116.36% | 104 144 -27.36% | 173 178 -2.91% | 85,7 111 -22.86% | -27,1 -6,00 -352.25% | 44,7 |
|
Net income Billions KRW | Released Forecast Spread | -3,64 22,4 -116.26% | 89,3 98,1 -9% | 137 106 28.91% | 65,5 69,2 -5.44% | -19,8 -4,22 -369.4% | 29,2 |
|
EPS KRW | Released Forecast Spread | -319 2 306 -113.84% | 7 101 9 078 -21.77% | 10 796 8 478 27.34% | 5 735 5 611 2.21% | -2 333 -383 -508.82% | 2 507 |
| Announcement Date | 11/02/20 | 09/02/21 | 14/02/22 | 14/02/23 | 31/01/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Billions KRW | Released Forecast Spread | 402 474 -15.13% | 417 383 8.96% | 423 417 1.39% | 460 473 -2.82% | 411 395 4.13% | 350 385 -9.17% | 433 441 -1.88% | 439 456 -3.6% | 405 426 -5.01% | 375 | 462 | 479 | 429 | 378 |
|
EBITDA Billions KRW | Released Forecast Spread | 29,6 | 42,0 | 39,8 | 13,8 | ||||||||||
|
EBIT Billions KRW | Released Forecast Spread | -13,9 34,2 -140.73% | 41,8 16,8 148.81% | 13,1 15,3 -14.52% | 48,8 55,1 -11.43% | -22,4 -5,55 -303.83% | -13,6 0,68 -2114.81% | 23,7 20,4 16.03% | 32,8 41,1 -20.16% | -8,41 -10,5 19.94% | 7,93 | 19,0 | 29,9 | 4,35 | 3,00 |
|
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 59,3 91,9 -35.49% | 12,3 13,8 -10.87% | 58,7 42,3 38.77% | -17,6 -0,49 -3517.74% | -21,0 -11,4 -85.02% | 6,30 20,4 -69.04% | 16,8 36,9 -54.41% | -29,2 -11,6 -153.21% | -13,4 | 9,00 | 35,0 | 13,0 | -1,00 | |
|
Net income Billions KRW | Released Forecast Spread | 65,4 59,6 9.82% | 12,9 11,0 16.92% | 37,5 45,4 -17.46% | 8,62 -4,80 279.6% | 1,80 16,8 -89.29% | 13,9 37,0 -62.43% | -19,9 -6,13 -223.95% | 4,07 | 6,75 | 16,7 | 3,20 | -1,00 | ||
| Announcement Date | 14/02/22 | 02/05/22 | 01/08/22 | 01/11/22 | 14/02/23 | 02/05/23 | 01/08/23 | 01/11/23 | 31/01/24 | - | - | - | - | - |
More events
Past sector events for GC Biopharma Corp.
| Today | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| Today | AMGEN INC.: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | CORCEPT THERAPEUTICS INCORPORATED: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | JAZZ PHARMACEUTICALS PLC: Q1 2024 Earnings Release |
| 01/05/2024 11:45 | PFIZER, INC.: Q1 2024 Earnings Release |
| 01/05/2024 08:00 | HALEON PLC: Q1 2024 Sales and Revenue Release - Trading Statement |
| 01/05/2024 07:00 | GSK PLC: Q1 2024 Earnings Release |
| 30/04/2024 | INNOVIVA, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PACIRA BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EYEPOINT PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- A006280 Stock
- Calendar GC Biopharma Corp.
